Tran Huyen Tran

Tran Huyen Tran

Auto-generated profile, based on publicly available information

Tran Huyen Tran

Binh Duong University, Ho Chi Minh City 75110, Vietnam

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


12 June 2026 in Natural and Life Sciences Communications
Verified
Journal Article
Closed access
TTTran Huyen Tran
Tran Huyen Tran
ULUt Van Le
Ut Van Le
HNHuong Thu Thi Nguyen
Huong Thu Thi Nguyen
TLTrieu Hai Ly
Trieu Hai Ly
Although Moringa oleifera, Vernonia amygdalina, and Centella asiatica are prominent tropical medicinal plants with various biological activities, the potential to allevate pancreatic oxidative stress and safety profile of a novel polyherbal formulation containing their leaf extracts have not been established. Therefore, this study was designed to evaluate the improvement in pancreatic oxidative stress and preclinical safety of this formulation. The pharmacological effects were evaluated in a streptozotocin-induced hyperglycemic mouse model. Preclinical safety was assessed according to OECD guidelines 423 (acute toxicity) and 407 (subchronic toxicity). After 7 days of treatment, the formulation (400 mg/kg) exhibited significant hypoglycemic activity. It also protected the pancreas against streptozotocin-induced oxidative stress by decreasing malondialdehyde (MDA) levels and increasing glutathione (GSH) concentrations in pancreatic tissue. In terms of safety, the formulation showed no acute toxicity, with an LD50 value greater than 5,000 mg/kg. During the 56-day subchronic toxicity study, the formulation (at 400 and 800 mg/kg) caused no mortality or significant changes in behavior and body weight. However, it did alter some biochemical, hematological, and histopathological parameters. Taken together, these findings suggest that the polyherbal formulation of M. oleifera, V. amygdalina, and C. asiatica extracts is a promising candidate for further development as a novel anti-hyperglycemic agent, although careful monitoring of its long-term effects is warranted.